Outlook Therapeutics (OTLK) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Outlook Therapeutics faces the risk of its common stock being delisted from The Nasdaq Capital Market if the company fails to meet the minimum bid price requirement by April 15, 2024. Despite a potential 180-day extension, the inability to maintain a share price above $1.00 for ten consecutive business days could lead to trading in the less favorable over-the-counter markets. This shift may significantly diminish stock liquidity and access to capital markets, potentially triggering a default under the December 2022 Note and undermining investor and stakeholder confidence.
Overall, Wall Street has a Moderate Buy consensus rating on OTLK stock based on 1 Buy and 1 Hold.
To learn more about Outlook Therapeutics’ risk factors, click here.
